EMA recommends authorisation of first veterinary vaccine using RNA technology

WHY IT MATTERS

While this veterinary vaccine approval doesn't directly treat human rare diseases, it demonstrates that RNA vaccine technology is advancing and becoming safer—knowledge that may eventually benefit human patients with rare genetic diseases through similar vaccine or gene therapy approaches.

The European Medicines Agency has approved a new vaccine for cats called Nobivac NXT HCPChFeLV that uses RNA technology to protect against common cat diseases. This is the first veterinary vaccine using this newer RNA technology approach. The vaccine can now be sold and used in European Union countries.

Source: European Medicines Agency (EMA) Description: EMA has recommended granting a marketing authorisation in the EU for Nobivac NXT HCPChFeLV, a vaccine for protecting cats against common infectious diseases.The vaccine… Published: 2026-04-17T12:59:00.000Z Note: EMA announcements cover medicines approved in the EU. Orphan designations may not yet be available in the US.